We have a deep preclinical autologous pipeline including new next-generation SPEAR T-cells, additional TCR targets, broader HLA coverage, HLA Independent TCR (HiT) therapies that eliminate the need for HLA restriction; and next-generation Tumor Infiltrating Lymphocyte (TIL) therapies.
We have built one of the leading allogenic T-cell platforms using human induced pluripotent stem cell lines (hIPCs). This platform is flexible, scalable, and produces functional T-cells that kill tumor cells in vitro. We will combine this platform with everything we have learned from decades of autologous T-cell therapy research and development into a pipeline for Adaptimmune and its partners for off-the-shelf cell or allogeneic T-cell therapies. We plan to file our first IND in 2023 for a wholly owned allogeneic therapy targeting MAGE-A4. We also have collaborations with Astellas and Genentech for future allogeneic therapies.